Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients.

@article{Kothary2011ProgressiveML,
  title={Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients.},
  author={Namita Kothary and Ida-Lina Diak and Allen Brinker and Shewit Bezabeh and Mark Avigan and Gerald J Dal Pan},
  journal={Journal of the American Academy of Dermatology},
  year={2011},
  volume={65 3},
  pages={
          546-551
        }
}
BACKGROUND Progressive multifocal leukoencephalopathy (PML), a rare, potentially fatal demyelinating disease, affects primarily immunocompromised individuals. The Food and Drug Administration (FDA) received reports of PML associated with efalizumab (Raptiva), a biologic agent approved for psoriasis. In July 2009, efalizumab was voluntarily withdrawn from the US market because of the risk of PML. OBJECTIVE To describe 3 cases of PML in psoriasis patients treated with efalizumab. METHODS The… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Genentech statement to Healthcare Professionals: Important safety information

  • Genentech, Inc
  • Available at: http://www. gene.com/gene/products…
  • 2009
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…